Your session is about to expire
← Back to Search
Behavioural Intervention
Study cohort for Human Immunodeficiency Virus Infection
N/A
Recruiting
Led By Maria Corcorran, MD, MPH
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
This trial will set up a pop-up clinic in a van near areas where women who inject drugs gather in north Seattle. The clinic will offer HIV prevention medication, opioid use disorder medication, and testing for
Who is the study for?
This trial is for women over 18 who inject drugs and are not known to have HIV. Participants must be willing to give informed consent, identify as female, and have a history of drug injection.Check my eligibility
What is being tested?
The study tests the effectiveness of a mobile van clinic in increasing the use of HIV prevention medication (PrEP) and treatments for opioid addiction among women who inject drugs. It also evaluates on-site STI testing's impact on treatment completion rates.See study design
What are the potential side effects?
Since this trial involves healthcare services rather than medications, there aren't typical side effects like with drugs. However, participants may experience discomfort or privacy concerns during testing or treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Evaluate uptake of PrEP and MOUD
Other outcome measures
Assess acceptability of POC STI testing at community-based site
Assess acceptability of pilot community-based care model
Evaluate sustained use of PrEP and MOUD
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Study cohortExperimental Treatment1 Intervention
The investigators will enroll 50 female-identifying people who present to the clinical van for care and follow them for 6 months. The investigators will assess uptake of PrEP and buprenorphine; POC STI testing and treatment completion rates; sustained use of PrEP and buprenorphine at months 3 and 6 (n=50). The investigators will conduct surveys to assess and characterize the acceptability and feasibility of venue-based primary and HIV prevention care among women who inject drugs (WWID).
Find a Location
Who is running the clinical trial?
University of WashingtonLead Sponsor
1,741 Previous Clinical Trials
1,847,710 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,470 Previous Clinical Trials
2,619,681 Total Patients Enrolled
Maria Corcorran, MD, MPHPrincipal InvestigatorUniversity of Washington
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available positions for patients to participate in this clinical trial?
"The clinical trial currently seeks suitable participants and was initially listed on the site on March 18, 2024. The latest update to its information was made on March 28 of the same year."
Answered by AI
What is the overall count of participants enrolled in this research endeavor?
"Affirmative. Information provided on clinicaltrials.gov indicates that this investigation is actively seeking eligible participants. The trial was initially published on March 18, 2024, and the most recent update occurred on March 28, 2024. Currently, they aim to enroll a total of 50 patients at one site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger